Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities:
Net loss	$ (6,864,676)	$ (2,410,673)
Adjustments to reconcile net loss to cash used in operating activities:
Extinguishment of note payable		32,316
Accrued interest	156,619	13,684
Amortization of debt discount	288,631	68,453
Stock-based compensation	1,977,155	624,052
Inducement expense	802,109
Amortization of intangible assets	120,872
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(636,497)	104,340
Accounts payable and accrued liabilities	267,002	919,968
Net cash used in operating activities	(3,888,785)	(647,860)
Cash Flows From Investing Activities:
Purchase of Tikkun Pharma license agreement	(44,143)
Net cash used in investing activities	(44,143)
Cash Flows From Financing Activities:
Proceeds from convertible notes payable	50,000	300,000
Proceeds from note payable, net of offering costs	1,812,410	238,000
Advances from related party		22,000
Offering and Reverse Merger proceeds	3,372,500
September 2020 private placement	227,500
December 2020 private placement	260,500
Repayment of note payable	(191,640)
Net cash provided by financing activities	5,531,270	560,000
Effect of foreign exchange rate on cash	(63,596)	17,903
Net increase (decrease) in cash	1,534,746	(69,957)
Cash - beginning of period	43,714	113,671
Cash - end of period	1,578,460	43,714
Supplemental non-cash financing activities:
Beneficial conversion feature issued with note payable	17,851
Warrants issued in conjunction with notes payable	32,149	24,875
Common stock issued for accounts payable	756,523
Common stock issued in conjunction with note payable modification	101,713	22,266
Notes payable issued to consultant for prepaid services		150,000
Conversion of related party advances and notes payable into common stock	679,569
Common stock issued for skincare license	$ 1,900,546